Provided by Tiger Trade Technology Pte. Ltd.

Assembly Biosciences

28.46
+0.95003.45%
Post-market: 28.460.00000.00%16:10 EDT
Volume:83.93K
Turnover:2.39M
Market Cap:450.16M
PE:-6.19
High:30.13
Open:30.13
Low:27.65
Close:27.51
52wk High:39.71
52wk Low:7.75
Shares:15.82M
Float Shares:7.55M
Volume Ratio:1.48
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6000
EPS(LYR):-6.6911
ROE:-5.10%
ROA:-4.02%
PB:2.18
PE(LYR):-4.25

Loading ...

Mizuho Securities Reaffirms Their Buy Rating on Assembly Biosciences (ASMB)

TIPRANKS
·
Nov 20, 2025

Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating

TIPRANKS
·
Nov 14, 2025

Assembly Biosciences Q3 EPS $(0.72) Beats $(0.78) Estimate, Sales $10.789M Beat $7.459M Estimate

Benzinga
·
Nov 11, 2025

Assembly Biosciences reports Q3 EPS (72c), consensus (65c)

TIPRANKS
·
Nov 11, 2025

Assembly Biosciences Q3 net loss narrows, raises $175 mln

Reuters
·
Nov 11, 2025

Assembly Biosciences reports positive interim results for ABI-5366 in Phase 1b genital herpes study

Reuters
·
Nov 11, 2025

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

THOMSON REUTERS
·
Nov 11, 2025

Assembly Biosciences Q3 Basic EPS USD -0.72

THOMSON REUTERS
·
Nov 11, 2025

Assembly Biosciences announces Phase 1b data for ABI-4334

TIPRANKS
·
Nov 07, 2025

Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334

Reuters
·
Nov 07, 2025

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

GlobeNewswire
·
Nov 07, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 06, 2025

Assembly Biosciences Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

Assembly Biosciences’ Promising HSV-2 Treatment Study: Key Insights for Investors

TIPRANKS
·
Oct 28, 2025

Assembly Biosciences’ ABI-6250 Study: A Potential Game-Changer in Hepatitis Treatment

TIPRANKS
·
Oct 28, 2025

Assembly Biosciences Files Prospectus Relates to Offering, Resale From Time to Time of up to 6.98 Mln Shares by Selling Stockholder

THOMSON REUTERS
·
Oct 15, 2025

Assembly Biosciences Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 14, 2025

Assembly Biosciences Announces Upcoming Investor Conference Participation

GlobeNewswire
·
Oct 14, 2025

Promising Phase 1b Results for ABI-5366 Drive Buy Rating for Assembly Biosciences

TIPRANKS
·
Oct 14, 2025

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

GlobeNewswire
·
Oct 10, 2025